Comparison · NCT02252536-sae
Sugar Pill vs Gabapentin Enacarbil: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sugar Pill vs Gabapentin Enacarbil: serious adverse events. Trial comparisons, record NCT02252536-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02252536-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0357 | 0.0165 | 0.0757 | wilson | |
| Risk in group 2 | 0.0471 | 0.024 | 0.0901 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0113 | -0.0585 | 0.0348 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.759 | 0.269 | 2.14 | log | |
| Odds ratio, group 1 over group 2 | 0.75 | 0.255 | 2.21 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Sugar Pill than on Gabapentin Enacarbil | 88.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sugar Pill | Matching placebo, sugar pill~Placebo: Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day | 6 | 168 | EG000 |
| Group 2 | Gabapentin Enacarbil | 600 mg Gabapentin Enacarbil (Horizant)~gabapentin enacarbil: Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day | 8 | 170 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- AEs were assessed from Week 1 - Week 29.
Source ClinicalTrials.gov
Trial
- Title
- HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder
- NCT number
- NCT02252536
- Phases
- PHASE2
- Conditions
- Alcohol Use Disorder
- Interventions
- gabapentin enacarbil, Placebo
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Results first posted
- 2018-09-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02252536?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02252536-sae